Ceritinib For Lung Cancer Treatment

Quincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.

Quincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.

Clinical Pearls:

  • Ceritinib is a second-generation ALK inhibitor
  • In a preclinical setting, ceritinib was found to have activity to the ALK-amplified cell lines as well as in human samples
  • Unlike crizotinib, ceritinib does have substantial CNS penetration ​